Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesRapid and sustained health utility gain in anti-TNF treated inflammatory arthritis. Observational data during seven years in southern Sweden
Annals of Rheumatic Diseases, 04/15/09
Gulfe A et al. – Study shows that utilities at inclusion remained largely unchanged for RA, PsA and SpA over 7 yrs; improvement occurred early during treatment. There were no major differences between RA, PsA and SpA. EQ-5D proved feasible and applicable across these diagnoses.
Methods- Study was initiated to:
- evaluate the secular trends in baseline health utilities in patients commencing TNF blockade for arthritis in clinical practice over 7 years
- address utility changes during treatment
- investigate the influence of previous treatment courses
- study the feasibility of health utility measures
- and compare them across diagnostic entities
- EuroQoL 5 Dimensions (EQ-5D) utility data were collected of anti-TNF treated pts with RA (N=2554), PsA (N=574) or SpA (N=586)
- Time trends were calculated; completer analysis was used
- Weak or non-significant secular trends for increasing baseline utilities over time for RA, PsA and SpA
- Max. gain in utilities occurred already after 2 wks for all diagnoses and remained stable for pts remaining on therapy
- First and second anti-TNF courses performed similarly
Related Articles
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor [alpha] therapies: Does the risk change with the time since start of treatment?
Arthritis & Rheumatism, 11/05/09
Relevance Score: 88%
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR)
Annals of Rheumatic Diseases, 11/13/09
Relevance Score: 82%
Lymphoma in patients treated with anti-TNF. Results of the 3-year prospective French RATIO registry.
Annals of Rheumatic Diseases, 10/22/09
Relevance Score: 80%
TNF{alpha} blockade impairs dendritic cell survival and function in rheumatoid arthritis [Extended Report]
Annals of Rheumatic Diseases, 10/07/09
Relevance Score: 80%
Reactivation of hepatitis B viral infection in inactive HBSAg carriers following anti-tumor necrosis factor-alpha therapy
Journal of Rheumatology, 10/05/09
Relevance Score: 80%
Today in Other Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
Platelet hyper-reactivity in active inflammatory arthritis is unique to the adenosine diphosphate pathway: A novel finding and potential therapeutic target
Rheumatology, 12/07/09
Site of psoriasis (scalp or intergluteal/perianal), >=3 affected sites, and nail dystrophy predicted psoriatic arthritis in incident psoriasis
Evidence-Based Medicine, 12/07/09
Long-term experience with etanercept in psoriatic arthritis patients: A 3-year observational study
Journal of Dermatological Treatment , 12/07/09
Sponsor
Article Search
Sponsor